文献速递药物不良反应与药物警戒

验证加拿大行政健康数据中识别不依从不良事件的方法

Validating methods used to identify non-adherence adverse drug events in Canadian administrative health data.
PubMed 文献 · Br J Clin Pharmacol · 2024-02-06

该研究基于2008至2015年不列颠哥伦比亚三个前瞻性队列的976例不良事件,将医院诊断的不依从作为金标准,评估药物索赔数据中不依从测量方法的敏感度和特异度。结果显示,不依从测量敏感度仅22.4%至37.5%,覆盖天数比例95%阈值表现最佳;不持续测量敏感度10.4%至58.3%,7天间隙最敏感但将61.2%样本判为不依从而医院仅诊断19.6%。结论认为行政数据库识别不依从的方法与医疗提供者金标准诊断相比不准确。

要点

  • 行政数据不依从测量敏感度低(22.4%–37.5%),覆盖天数比例95%阈值最佳。
  • 7天间隙不持续测量最敏感但将61.2%样本判为不依从,远高于医院诊断的19.6%。
  • 依赖行政数据识别不依从会低估问题规模并可能误判依从患者为不依从。

核心结论

  • 行政数据库中识别不依从的方法与医疗提供者金标准诊断相比不准确。
  • 依赖行政数据识别不依从的研究低估问题规模并可能误标依从患者为不依从。

研究设计与样本

  • 回顾性分析2008至2015年不列颠哥伦比亚三个前瞻性队列中诊断的不良药物事件(n=976)。
  • 将前瞻性识别的不良事件链接至药物索赔数据,评估典型不依从测量的敏感度和特异度。

主要发现

  • 不依从测量敏感度范围为22.4%至37.5%,覆盖天数比例95%阈值表现最佳。
  • 不持续测量敏感度范围为10.4%至58.3%,7天间隙最敏感但将61.2%样本分类为不依从。
  • 医院诊断的不依从比例仅为19.6%。

关键数值与推荐

  • 覆盖天数比例阈值95%在不依从测量中表现最佳(敏感度范围22.4%–37.5%内)。
  • 7天间隙不持续测量最敏感(敏感度范围10.4%–58.3%内),但分类61.2%样本为不依从。

临床怎么用

  • 临床药学智能体应谨慎解读基于行政索赔数据的不依从识别结果,避免直接用于患者分类。
  • 需结合医院诊断等金标准确认不依从,而非单独依赖行政数据测量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Medication non-adherence is a type of adverse drug event that can lead to untreated and exacerbated chronic illness, and that drives healthcare utilization. Research using medication claims data has attempted to identify instances of medication non-adherence using the proportion of days covered or by examining gaps between medication refills. We sought to validate these measures compared to a gold standard diagnosis of non-adherence made in hospital. METHODS: This was a retrospective analysis of adverse drug events diagnosed during three prospective cohorts in British Columbia between 2008 and 2015 (n = 976). We linked prospectively identified adverse drug events to medication claims data to examine the sensitivity and specificity of typical non-adherence measures. RESULTS: The sensitivity of the non-adherence measures ranged from 22.4% to 37.5%, with a proportion of days covered threshold of 95% performing the best; the non-persistence measures had sensitivities ranging from 10.4% to 58.3%. While a 7-day gap was most sensitive, it classified 61.2% of the sample as non-adherent, whereas only 19.6% were diagnosed as such in hospital. CONCLUSIONS: The methods used to identify non-adherence in administrative databases are not accurate when compared to a gold standard diagnosis by healthcare providers. Research that has relied on administrative data to identify non-adherent patients both underestimates the magnitude of the problem and may label patients as non-adherent who were in fact adherent.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wickham ME, McGrail KM, Law MR, et al. Validating methods used to identify non-adherence adverse drug events in Canadian administrative health data. Br J Clin Pharmacol. 2024. PMID: 38320955. doi:10.1111/bcp.16014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。